K. Pendergrass

发表

Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group.

M. Kris, R. Gralla, B. Gertz, 1999, The New England journal of medicine.

The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with non-clear cell (NCC) renal cell carcinoma (RCC)

R. Figlin, S. Srinivas, M. Ernstoff, 2007 .

A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study

R. Advani, V. Bolejack, E. Jacobsen, 2013, Leukemia & lymphoma.

Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology

M. Lichinitser, G. Jerusalem, Miguel Martín, 2013, Breast Cancer Research and Treatment.

Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.

D. Kerr, J. Hainsworth, J. Hecht, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-line vs second-line fulvestrant for hormone receptor-positive advanced breast cancer: A post-hoc analysis of the CONFIRM study.

G. Jerusalem, Miguel Martín, A. Di Leo, 2018, Breast.

PYRAMID and LYM2034: Targeted randomized phase II studies of bortezomib with or without immunochemotherapy in newly diagnosed nongerminal center B-cell-like (GCB) diffuse large B-cell lymphoma (DLBCL), including rapid prospective non-GCB subtype identification.

J. Reeves, I. Flinn, J. Hajdenberg, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

High-dose chemotherapy and peripheral blood stem cell infusion in patients with non-Hodgkin’s lymphoma: results of outpatient treatment in community cancer centers

J. Hainsworth, F. Greco, L. Schwartzberg, 1997, Bone Marrow Transplantation.

Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone.

M. Kris, R. Navari, B. Ferguson, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CONFIRM: A Phase III, Randomized, Parallel-Group Trial Comparing Fulvestrant 250 mg vs Fulvestrant 500 mg in Postmenopausal Women with Estrogen Receptor-Positive Advanced Breast Cancer.

M. Lichinitser, A. Leo, G. Jerusalem, 2009 .

A meta-analysis of two randomized, double-blind, placebo-controlled, phase III studies in patients (pts) with metastatic colorectal cancer (mCRC) receiving FOLFOX4 and PTK/ZK to determine clinical benefit on progression-free survival (PFS) in high LDH pts.

D. Kerr, E. Van Cutsem, J. Douillard, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer

J. Hainsworth, L. Bosserman, H. Burris, 2017, Breast Cancer Research and Treatment.

Intensive timed sequential combination chemotherapy in extensive-stage small cell carcinoma of the lung.

M. Markman, M. Abeloff, K. Pendergrass, 1982, Cancer treatment reports.

A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy.

J. Hainsworth, D. Gandara, P. Hesketh, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer.

P. Goss, W. Miller, I. Bondarenko, 2007, Journal of Clinical Oncology.

Final analysis of overall survival for the Phase III CONFIRM trial: fulvestrant 500 mg versus 250 mg

A. Leo, G. Jerusalem, M. Martín, 2012 .

Unfavorable histologies of non-Hodgkin's lymphoma treated with ProMACE-CytaBOM: a groupwide Southwest Oncology Group study.

R. Fisher, T. Miller, H. Eyre, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Options in the treatment of chemotherapy-induced emesis.

K. Pendergrass, K. B. Pendergrass, 1998, Cancer practice.

Efficacy of Oral Ondansetron, A Selective Antagonist of 5‐HT3 Receptors, in the Treatment of Nausea and Vomiting Associated with Cyclophosphamide‐Based Chemotherapies

L. Cubeddu, K. Pendergrass, M. Meshad, 1994, American journal of clinical oncology.

Stratified, randomized, double-blind comparison of intravenous ondansetron administered as a multiple-dose regimen versus two single-dose regimens in the prevention of cisplatin-induced nausea and vomiting.

J. Hainsworth, D. Gandara, J. Kish, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

S. Swain, C. Vogel, S. Wadler, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia.

J. Bussel, C. Kessler, L. Aledort, 2014, Blood.

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

M. Lichinitser, G. Jerusalem, Miguel Martín, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final Overall Survival: Fulvestrant 500mg vs 250mg in the Randomized CONFIRM Trial

Didier Verhoeven, Guy Jerusalem, M. Lichinitser, 2013, Journal of the National Cancer Institute.

Randomized phase III Study of 5‐fluorouracil plus high dose folinic acid versus 5‐fluorouracil plus folinic acid plus methyl‐lomustine for patients with advanced colorectal cancer

B. Levin, R. Winn, L. Levy, 1995 .

Oral dolasetron mesylate in patients receiving moderately emetogenic platinum-containing chemotherapy. Oral Dolasetron Dose Response Study Group.

B. Karlan, R. Figlin, C. Benedict, 1997, The cancer journal from Scientific American.

A randomized, multicenter, phase (Ph) III study comparing carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) to LEN and Dex in patients (Pts) with relapsed multiple myeloma (MM).

A. Jakubowiak, D. Siegel, P. Moreau, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

M. Lichinitser, G. Jerusalem, Miguel Martín, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Efficacy of Oral Ondansetron, A Selective Antagonist of 5‐HT3 Receptors, in the Treatment of Nausea and Vomiting Associated with Cyclophosphamide‐Based Chemotherapies

L. Cubeddu, K. Pendergrass, M. Meshad, 1994, American journal of clinical oncology.

Oncology comparative effectiveness research: a multistakeholder perspective on principles for conduct and reporting.

Ya-Chen Tina Shih, S. Ramsey, D. Patt, 2013, The oncologist.

TPI 287, a third-generation taxane, is active and well tolerated as 2nd line therapy after failure of docetaxel in hormone refractory prostate cancer (HRPC)

S. Silberman, K. Pendergrass, M. Gross, 2008 .